@article{bd455948bbcc498d870ea68226ecb24a,
title = "Improvement in right ventricular strain with ambrisentan and tadalafil upfront therapy in scleroderma-associated pulmonary arterial hypertension",
author = "Valentina Mercurio and Monica Mukherjee and Tedford, {Ryan J.} and Zamanian, {Roham T.} and Khair, {Rubina M.} and Takahiro Sato and Minai, {Omar A.} and Fernando Torres and Girgis, {Reda E.} and Kelly Chin and Rachel Damico and Kolb, {Todd M.} and Mathai, {Stephen C.} and Hassoun, {Paul M.}",
note = "Funding Information: This research was supported by a research grant from TEVA Pharma. Funding Information: Supported by the Scleroderma Foundation (M.M.), NIH (grants P50 HL084946, R01HL114910, and U01HL125175 to P.M.H.), Gilead, United Therapeutics, and a grant from the Italian Society of Cardiology–Merck Sharp and Dohme (V.M.). Gilead Inc. and United Therapeutics Inc. provided the ambrisentan and tadalafil, respectively, free of charge for the entire duration of the study (36 wk) and for 1 year after completion of the study. They had no role in the design or monitoring of the study, acquisition of clinical or imaging data, statistical analysis, interpretation of the results, or writing of the manuscript.",
year = "2018",
month = feb,
day = "1",
doi = "10.1164/rccm.201704-0789le",
language = "English (US)",
volume = "197",
pages = "388--391",
journal = "American Review of Respiratory Disease",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3",
}